

Cancer Council Australia

ABN 91 130 793 725

Financial Report

for the year ended 30 June 2019

About Cancer Council Australia

The Cancer Council Federation is Australia's leading non-government cancer control* organisation. The national office, Cancer Council Australia, advises the Australian Government and other bodies on practices and policies to help prevent, detect and treat cancer. Cancer Council Australia also supports its members, the state and territory Cancer Councils, to achieve our shared purpose. Collectively we advocate for the rights of people affected by cancer and in particular for best treatment and supportive care in order to reduce the burden of cancer in the Australian community.

Our vision

A cancer free future.

Our purpose

We are Australia's leading cancer charity, uniting the community, providing support, investing in research and saving lives.

Our activities

Reflecting our stated strategic plan Cancer Council Australia works to:

1. Shape and influence policy and practice across the cancer control continuum
2. Develop and disseminate evidence-based cancer information
3. Convene and collaborate with cross sectorial stakeholders and consumers to set priorities and mobilise action
4. Be a trusted voice for cancer control in Australia

Our history

Cancer Council Australia commenced in 1961 as the *Australian Cancer Society*, an incorporated association, when the six state Cancer Councils – which then varied in name and brand – agreed to establish a federal body to promote cancer control at the national level. Cancer organisations in the ACT and the Northern Territory were subsequently formed and signed on as members of the Society.

While state and territory Cancer Councils continued to play the predominant role in research, public health, patient support and education programs, the federal body's primary role was to develop independent national cancer control policy – albeit on a comparatively modest scale, in collaboration with our members.

In 1997, the eight jurisdictional members agreed to expand the Society, adopting the trading name of *The Cancer Council Australia* and appointing an expert Chief Executive Officer, Professor Alan Coates, to lead the push for improved national cancer control policy and build the Cancer Council brand and profile. Specialist staff in communications, advocacy, business management, marketing and other professional roles were recruited to promote the organisation's mission.

Over the ensuing decade, state and territory members uniformly adopted the name Cancer Council and together took on the image of the daffodil, a global symbol of hope, as our common logo.

In 2008, the organisation migrated from being registered as an Incorporated Association to a Company Limited by Guarantee, and formalised its registered name as *Cancer Council Australia*.

Cancer Council Australia is also allied with the *Clinical Oncology Society of Australia*, which provides advice on medical and scientific issues, and is a member of the *Australian Chronic Disease Prevention Alliance*, as well as global collaborations such as the *Union for International Cancer Control*.

Over its 58-year history, Cancer Council Australia has transformed from a small secretariat to a strong federal body that has become Australia's leading independent authority on cancer control.

Cancer Council Australia seeks to engage all Australians in our work to reduce the impact of cancer in Australia through advocacy, research, education and support.

*Cancer control refers to actions to reduce the impact of cancer on people including: reducing cancer risk and incidence; improving early detection and treatment; and improving care and support for people affected by cancer.

Cancer Council Australia

(A Company limited by guarantee)

Corporate Information

ABN 91 130 793 725

Patron

Sir Gustav Nossal AC CBE

Directors as at 30 June 2019

Mr Hugh Harley
Mr David Bowker
Professor Fran Boyle
Ms Annette Burke
Ms Trisha Cashmere
Dr Judith Dwyer
Dr Anita Green
Ms Sue Hart
Dr John Laker AO
Professor Jeremy Millar
Ms Jenny Parker
Associate Professor Marion Saville
Professor George Yeoh

Company Secretary

Ms Lisa Miskell

Chief Executive Officer

Professor Sanchia Aranda AM

**Registered office and
principal place of business**

Level 14
477 Pitt Street
Sydney NSW 2000

Company contact details

GPO Box 4708
Sydney NSW 2001

P: +61 (0)2 8063 4100

F: +61 (0)2 8063 4101

E: info@cancer.org.au

W: www.cancer.org.au

Auditors

BDO East Coast Partnership
Level 11
1 Margaret Street
Sydney NSW 2000

Cancer Council Australia (ABN 91 130 793 725)

Directors' Report

30 June 2019

The Directors present their report on Cancer Council Australia ("the Company") for the year ended 30 June 2019.

Reflecting the Company's vision and purpose, our object is to advance and achieve the following goals as a charitable institution operating in Australia to:

- i. Promote the prevention and control of cancer;
- ii. Reduce the incidence of preventable cancers;
- iii. Reduce deaths from cancer;
- iv. Foster and support high quality cancer research in Australia; and,
- v. Improve survival from cancer.

Consistent with this, Cancer Council Australia is committed to:

- i. Working in partnership with members and collaborating with people affected by cancer, health professionals, health service providers, Government and non-Government agencies in improving cancer control;
- ii. Providing strategic leadership in cancer control;
- iii. Supporting and enabling the charitable work of members, who are themselves charitable entities that have a similar charitable purpose to Cancer Council Australia;
- iv. Driving national collaboration and harmonisation in cancer control;
- v. Being a trusted source of cancer information and evidence in cancer control;
- vi. Being a leader in national and international policy and advocacy in cancer control;
- vii. Fostering partnerships that reduce the impact of cancer on our communities;
- viii. Promoting best practice in all aspects of cancer control; and,
- ix. Enhancing quality of life for people affected by cancer.

In pursuing these objectives the Company's primary short-term objectives over the reporting period were:

- Public health advocacy - focused on the National Bowel Cancer Screening Program, National Tobacco Strategy, strengthened obesity control policies, skin cancer prevention, and advancing the agenda for occupational cancers
- Clinical practice – Develop and promote clinical practice guidelines on our wiki platform, and online educational resources for health professionals and supporting the implementation of optimal care pathways
- Improving public understanding of the work and impact of Cancer Council.

The Year In Review

Cancer Council Australia commenced implementation of its three-year strategic plan with a core focus on reducing inequalities in cancer outcomes and supporting a high functioning Cancer Council federation.

Several new initiatives were implemented during the year including:

- Launching Australia's first national mass media campaign to promote bowel cancer screening participation and reduce the burden of bowel cancer in Australia, following a \$10 million grant from the Commonwealth Department of Health.
- Launching our draft Informed Financial Consent Standard for public consultation, with our partners the Breast Cancer Network Australia, Prostate Cancer Foundation of Australia, and CanTeen.
- Conducting the Optimising the Early Detection of Breast Cancer project in collaboration with Breast Screen Australia and the Commonwealth Department of Health.
- Developing a proactive approach to highlighting inequalities in cancer outcomes in the Australian media through commentary on new reports and research.
- Commencing work on our first Reconciliation Action Plan.
- Joining with leading health organisations to launch new guidelines for daily sunscreen use.

Cancer Council Australia (ABN 91 130 793 725)

Directors' Report (cont'd)

30 June 2019

We also continued our ongoing priority programs to educate and inform Australians about cancer prevention and support individuals affected by cancer, including:

- Joining with the Australasian College of Dermatologists to remind Australians to protect their skin from UV, during National Skin Cancer Action Week.
- Using World Cancer Day as a platform to promote cancer prevention – highlighting new Cancer Council funded research showing the number of cancer cases that could be avoided in the future if more Australians maintained a healthy weight and exercised.
- Partnering with Cancer Council NSW to promote new research showing Australia is on track to eliminate cervical cancer as a public health issue.
- Partnering with Cancer Council Victoria on media activity for World No Tobacco Day, highlighting a concerning increase in the usage of roll-your-own tobacco amongst teenagers.
- Partnering with Cancer Council NSW to highlight new modelling showing reducing the smoking rate to below 10 per cent could save 100,000 lives.
- Using media channels and digital platforms to encourage Australians to prevent cancer by quitting smoking, using sun protection, maintaining a healthy diet and lifestyle and participating in screening programs.
- Improving supportive care collaboration and data across the federation to better understand opportunities for service improvement.
- Continually enhancing and updating our digital cancer information.

Principal activities

The principal activities of Cancer Council Australia during the year were focused on furthering our objectives, referenced above. More detail on the achievements against these objectives are detailed in the 2018-2019 Annual Review. This financial report pertains only to Cancer Council Australia and does not aggregate income or expenditure across State and Territory members.

Review of financial operations and results of Cancer Council Australia

The total income for the financial year ended 30 June 2019 was \$13,264,490. In the same period, expenditure was \$13,007,663 leaving a surplus of \$256,827. The level of spending for the Company varies from year to year as the range of activities to support our members, and the costs associated with them, also vary. This expenditure includes our investment in health strategies and activities to reduce the impact of cancer. Further details are outlined in the Driving Change and Sharing Information sections of Cancer Council Australia 2018-2019 Annual Review.

Matters subsequent to the end of Financial Year

The Directors are not aware of any significant events that have occurred since the end of the reporting period which would impact on the financial position of the Company disclosed in the Statement of Financial Position as at 30 June 2019 or on the results and cash flows of the Company for that year.

Indemnity and insurance of officers

The Company has indemnified the Directors and Executives of the Company for costs incurred, in their capacity as a Director or Executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Company paid a premium of \$9,923 in respect of a contract to insure the Directors and Executives of the Company against a liability to the extent permitted by the Corporations Act.

Indemnity and insurance of auditor

The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor.

During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity.

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2019

Proceedings on behalf of the Company

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

Environmental Regulation

The Company is not subject to any significant environment regulations.

Dividends

The Company does not permit any dividends and therefore no dividends have been paid or declared.

Directors

The names of the Directors of the Company in office during or since the end of the year are:

Directors Name, Qualifications and Experience	Role	Date Joined	Date Ceased	Board	Executive Committee	Governance Committee	Finance, Risk & Audit Committee
All Directors of the Company in office during the financial year.							
Attended / Eligible to attend							
Dr Judith Dwyer AM Ph.D, MBA, BA, FAICD, FCHSM Dr Dwyer is an adjunct professor in health care management at the Flinders University College of Medicine and Public Health, and a former CEO of Southern Health Care Network in Melbourne and Flinders Medical Centre in Adelaide, having worked in the Australian health system for more than 20 years. She was recently awarded the Sidney Sax Medal for her life-long contribution to the health system. She continues to conduct research focused on health system governance and design with a focus on Aboriginal health policy and services. She is the lead author of the popular textbook Project Management in Health and Community Services.	Director - Board (from 26 Feb 19) Deputy Chair - Board (up to 26 Feb 19) Member - Executive Committee Chair - Governance Committee	17 Oct 2013	-	6/6	2/2	4/4	
Professor George Yeoh BSc(Hons) PhD Professor Yeoh served on the Research Grants Committee of Cancer Council WA from 1999 to 2009, the last eight years of which he was Chair. In 2009, he joined the Board of Cancer Council WA and was appointed President in 2014 and currently a Board member of Cancer Council Australia. He is a Senior Honorary Research Fellow in the School of Molecular Sciences and an Emeritus Professor in the School of Biomedical Sciences at the University of Western Australia. Professor Yeoh undertakes research at the UWA and the Harry Perkins Institute of Medical Research. He has had a long-term interest in liver development and cancer. He was a Board member of The Institute for Respiratory Medicine, Director of the UWA Centre for Cell Therapy and Regenerative Medicine, and a member of the National Health and Medical Research Council's Translational Research Faculty. He served on the Cancer Australia Advisory Council from 2015-2018.	Director - Board	11 Dec 2013	-	5/6			
Dr Anita Green MBBS, MSPMed, FRACGP, FASMF, FAICD Dr Green is a Deputy Chair of Cancer Council Queensland and Chair of the Brisbane North Primary Health Network. She works at the University of Queensland Health Service as a General Practitioner, is a Visiting Medical Officer at The Prince Charles Hospital, and was Chief Medical Officer for the 2018 Gold Coast Commonwealth Games. Dr Green is an experienced medical educator, with an appointment as a part-time Senior Lecturer with the University of Queensland School of Human Movement and Nutrition Sciences. She has over 20 years' experience on not-for-profit Boards in the health sector.	Director - Board Member - Finance Risk & Audit Committee (from 14 Aug18)	3 Feb 2014	-	6/6			4/5
Ms Annette Burke BA Hons, Dip Ed, MEd, MBA, ARLP Fellow Ms Burke is Chair of the Board of Cancer Council NT and Fellow of the Australian Rural Leadership Foundation. Having worked for the Abu Dhabi Government as Curriculum Manager at the Centre of Excellence and Director of Executive Education at the Abu Dhabi Chamber of Commerce, Ms Burke negotiated the first ever partnership with five of the world's leading education institutions – Oxford, Cambridge, Harvard, London Business School, Singapore Civil Service College and the National School of Government UK. Ms Burke was Mayor of Palmerston City Council from 1997 to 2007. She has post-graduate qualifications in education, international relationships and negotiations, and business administration.	Director - Board Member - Finance Risk & Audit Committee	7 Nov 2014	-	5/6			3/6
Professor Jeremy Millar BMedSci MB ChB FRANZCR FChPMed Professor Millar is also the Board Chair, Cancer Council Victoria; Professor at the Central Clinical School, Monash University; and Council Member, Faculty of Radiation Oncology, Royal Australian and New Zealand College of Radiology (RANZCR). He is the Research Director, Radiation Oncology, Alfred Health, where he has a clinical practice specialising in genito-urinary cancers. Jeremy has more than a 100 publications in peer-reviewed research journals; mostly in brachytherapy, clinical quality registries, or prostate cancer, and has lead academic roles in multiple state, national and international cancer outcomes quality registries at the School of Public Health and Preventive Medicine, Monash University.	Director - Board	22 May 2015	-	5/6			

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2019

Directors Name, Qualifications and Experience	Role	Date Joined	Date Ceased	Board	Executive Committee	Governance Committee	Finance, Risk & Audit Committee
All Directors of the Company in office during the financial year.							
<p>The Hon. Nicola Roxon BA/LLB (Hons), GAICD</p> <p>The Hon. Nicola Roxon is a well-respected figure in Australian public health. As Australia's Health Minister from 2007-2011, Ms Roxon held responsibility for the Federal Government's \$64 billion health portfolio and led key public health initiatives, including the introduction of Australia's world-first plain packaging tobacco legislation. In 2011 she was appointed Australia's first female Attorney General. Since her retirement from Parliament in 2013, Ms Roxon has developed a career as a non-executive director. She is currently the independent Chair of Hesta, Chairman of the Accounting Professional and Ethical Standards Board and the Sir Zelman Cowen Centre and a non-executive Director of Dexu and Lifestyle Communities.</p>	<p>Chair - Board (up to 26 Feb 19)</p> <p>Chair - Executive Committee (up to 26 Feb 19)</p> <p>Ex-officio Member - Governance Committee (up to 26 Feb 19)</p> <p>Ex-officio - Finance Risk & Audit Committee (up to 26 Feb 19)</p>	17 June 2015	26 Feb 2019	5/5	2/2	2/3	2/3
<p>Mr Hugh Harley M.Phil LLB (Hons) BEc (Hons) SF (Fin)</p> <p>Hugh Harley has had a diverse career, across the public and private sectors, banking, professional services, and academia. Among executive experience, he was until recently partner in professional services at PwC Australia, specialising in strategy, risk, and governance, and prior to held senior roles in Commonwealth Bank, including head of Retail Banking and of Group Strategy. Among non-executive roles, he has been Chairman of the Audit Committee of ING Bank Australia and Director of ASB Bank NZ. Mr Harley is Adjunct Professor at the Sydney University Economics School, where he teaches on the current implications of economic history. Mr Harley has previously held Chairman, Treasurer and Board positions in a variety of not-for-profit organisations, across professional services, education, child welfare, and charitable sectors. He was appointed Chairman of Cancer Council Australia on 27 August 2019.</p>	<p>Acting Chair/Deputy Chair - Board (from 26 Feb 19)</p> <p>Director - Board (up to 26 Feb 19)</p> <p>Acting Chair - Executive Committee (from 26 Feb 19)</p> <p>Member - Executive Committee (up to 26 Feb 19)</p> <p>Ex-officio Member - Governance Committee (from 26 Feb 19)</p> <p>Ex-officio Member - Finance Risk & Audit Committee (from 26 Feb 19)</p> <p>Chair - Finance Risk & Audit Committee (up to 26 Feb 19)</p>	24 May 2016	-	6/6	2/2	1/1	6/6
<p>Ms Sue Hart BA MBUS FAICD</p> <p>Sue Hart has extensive experience in the public and private sectors in both Australia and overseas, and is currently a Director and senior consultant at CMS – an Association Management Company. In this role, Ms Hart provides specialist services to a number of public and private sector boards, assisting with corporate governance, compliance and effectively recording their deliberations, as well as assisting their Chairs in their management roles. She has been awarded a Fellowship of the Australian Institute of Company Directors (AICD) in recognition of her extensive work in corporate governance at a business and personal level, including publication of a number of papers regarding governance processes and provisions in the not for profit sector.</p>	<p>Director - Board</p> <p>Member - Governance Committee</p>	16 Aug 2016	-	5/6		4/4	
<p>Professor Phyllis Butow BA (Hons), Dip Ed, M Clin Psych, MPH, PhD</p> <p>Professor Butow is a NHMRC Principal Research Fellow, Foundation Director of the Centre for Medical Psychology and Evidence-based Decision-making (CeMPED), and Foundation Chair of the Psycho-Oncology Co-Operative Research Group (PoCoG) at the University of Sydney. She has worked for over 20 years in the area of psycho-oncology and has developed an international reputation in psycho-oncology research and health communication.</p>	<p>Director - Board (up to 21 Nov 2018)</p>	23 Nov 2016	21 Nov 2018	3/4			
<p>Ms Trisha Cashmere BAppSc(Phy)Hons LLB GAICD</p> <p>Ms Cashmere is the consumer representative on Cancer Council Australia's Board. She has practised as a physiotherapist in the public and private sectors, and as a commercial lawyer, and now heads up a growing health business. She has held a number of Board Director positions in the health sector. Ms Cashmere brings personal experience of cancer to her role, as the mother of a child who has twice been diagnosed with cancer.</p>	<p>Director- Board</p> <p>Acting Chair - Finance Risk & Audit Committee (from 21 May 19)</p> <p>Member - Finance Risk & Audit Committee (up to 21 May 19)</p>	21 Feb 2017	-	6/6			5/6
<p>Mr Roger Traves QC</p> <p>Roger Traves QC is a member of the Queensland Bar and was appointed Senior Counsel in 2003. Mr Traves specialises in commercial law, administrative and public law and is a former president of the Bar Association of Queensland. He is a senior member of Level Twenty Seven Chambers, the largest barristers' chambers in Queensland, and is currently the Deputy-Chair of the Board of Directors, Cancer Council Queensland, and a member of the Finance Audit and Risk Management Committee. Mr Traves is the past president of the Breast and Prostate Cancer Association of Queensland.</p>	<p>Director - Board (up to 02 Aug 2018)</p> <p>Member - Governance Committee (up to 02 Aug 2018)</p>	21 Feb 2017	02 Aug 2018	1/2		0/2	

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2019

Directors Name, Qualifications and Experience	Role	Date Joined	Date Ceased	Board	Executive Committee	Governance Committee	Finance, Risk & Audit Committee
All Directors of the Company in office during the financial year.	Attended / Eligible to attend						
<p>Mr David Bowker BSc MComm GAICD</p> <p>David is the Vice President of Cancer Council Tasmania and has an Engineering degree from the UK and a Master of Commerce degree from Cape Town University. David has worked for Caltex and de Beers in several countries prior to joining Hydro Tasmania in 1991. During his time at Hydro Tasmania David was the inaugural winner of the Sir Allan Knight Scholarship which allowed him to study energy markets in the UK. David has had roles within Hydro Tasmania in information technology, corporate strategy and energy policy areas. David retired from Hydro Tasmania in December 2016 but still chairs an international working group studying the application of block chain technology to electricity markets. David was the deputy chairman of the board of the National Generators Forum for 6 years, an industry association of electricity generators across Australia. His particular interests lie in strategy and governance and he is Chair of the Governance Committee for Cancer Council Tasmania.</p>	Director - Board Member - Governance Committee	7 Oct 2017	-	5/6		4/4	
<p>Associate Professor Marion Saville MBChB, Am Bd (Anat Path & Cytopath), FIAC, Grade Dip Med (Clin Epi), GAICD</p> <p>Associate Professor Marion Saville is Executive Director of the Victorian Cytology Service, a position she has held since 2000. Marion Saville is a New Zealand medical graduate who trained in Anatomic Pathology at Northwestern University in Chicago. She went on to complete a fellowship in Cytopathology at East Carolina University and a research fellowship at Georgetown University, focussing on HPV. After completing her pathology training she returned to NZ and later to Australia, where she completed a Graduate Diploma in Clinical Epidemiology at the University of Sydney. Marion has held a number of leadership positions, in cytopathology laboratories in Auckland, Sydney and Melbourne. She is a past president of both the New Zealand and the Australian Societies of Cytology and she chaired the ASC Board of Examiners from 2009 until 2013. She is co-Principal Investigator on the Compass trial, Australia's largest clinical trial, examining the performance of HPV based cervical screening compared with cytology based screening. It is the first large scale clinical trial internationally to assess these screening tests in an HPV vaccinated population. Marion has served on numerous cervical screening advisory committees in Australia and New Zealand. Most recently she was a member of the Renewal Steering Committee, a group established by Australian governments to provide oversight to "Renewal" of the National Cervical Screening Programme. She was also Deputy Chair on the Australian Government's Department of Health and Ageing's Working Party to draft "Clinical Management Guidelines for the Prevention of Cervical Cancer". She is currently chairing the New Zealand Government's, Technical Reference Group who provide expert advice and skills to the National Screening Unit in its implementation of HPV primary screening in the New Zealand National Cervical Screening Programme and is HPV Testing Implementation Consultant for the Ontario Cervical Screening Program for Cancer Care Ontario Canada.</p>	Director - Board	22 Nov 2017	-	5/6			
<p>Dr John Laker AO BEc (Hons 1) (Syd), MSc (Econ) PhD (London), HonDSc (Syd)</p> <p>Dr Laker was Chairman of the Australian Prudential Regulation Authority (APRA), the regulator of the Australian financial services industry, from 2003 to 2014. An economist by training, Dr Laker had an extensive career in the Reserve Bank of Australia prior to his appointment to APRA, both in Australia and London, and has also worked in the Commonwealth Treasury and the International Monetary Fund (IMF). Currently, Dr Laker is an External Expert for the IMF and has participated in a number of reviews of major banking systems. He is a member of the External Advisory Panel of the Australian Securities and Investments Commission. He is Chairman of The Banking and Finance Oath Ltd, Deputy Chancellor and member of the Council of the University of Technology Sydney, a Director of Cancer Council NSW and a Director of ING Bank (Australia). He also lectures at the University of Sydney. Dr Laker was made an Officer of the Order of Australia in 2008 and has won other professional awards for his services to the regulation of the Australian financial system.</p>	Director - Board	8 May 2018	-	4/6			
<p>Professor Fran Boyle AM, MBBS (QLD) FRACP PhD (Sydney) GAICD</p> <p>Fran Boyle is a Medical Oncologist at North Sydney's Mater Hospital, where she is Director of the Patricia Ritchie Centre for Cancer Care and Research, and Professor of Medical Oncology at the University of Sydney. She has been involved in clinical trials, supportive care and psychosocial research in breast cancer for the past 20 years. Fran is president elect of the Clinical Oncology Society of Australia, and is a Director of the Breast Cancer Network of Australia.</p>	Director - Board	19 Dec 2018	-	2/2			
<p>Ms Jenny Parker</p> <p>Jenny has more than 25 years professional services experience, and has been a Partner with Ernst & Young since 1999. Jenny leads the whole of firm in Australia and New Zealand in EY's market facing activities for Health and Life Sciences. Jenny also has a proven track record in leading outsourced internal audit functions, she has also served as the Queensland Managing Partner and on EY's Area Advisory Council responsible for the firm's overall governance and direction. Jenny has held numerous board positions and is currently serving as Deputy Chancellor Audit Committee and Council member of Queensland University of Technology, Chair of the Catholic Education Council, Council Member of Marcy Partners, Member of the Archdiocesan of Brisbane Finance Council and external advisor to the Queensland Museum Finance Audit and Risk Management Committee. Jenny is a Fellow of the Institute of Chartered Accountants and member of the Institute of Internal Auditors.</p>	Director - Board	07 Feb 2019	-	1/2			

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2019

Chief Executive Officer

Professor Sanchia Aranda was appointed as the CEO to the Company on 3 August 2015.

Company Secretary

Linda Monk was appointed Company Secretary on 1 June 2018 and resigned on 14 December 2018.

Ryan Alexander was appointed interim Company Secretary from 14 December 2018 until 11 March 2019.

Lisa Miskell was appointed Company Secretary on 11 March 2019.

Contributions on winding up


In the event of the Company being wound up, ordinary members are required to contribute a maximum of \$10 each.

Auditor's Independence Declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on the following page.

This report is made in accordance with a resolution of Directors, pursuant to section 298(2) (a) of the Corporations Act 2001.

On behalf of the Directors



Mr Hugo Harley

Chair



Dr John Laker

Sydney
22 October 2019

DECLARATION OF INDEPENDENCE BY PAUL CHEESEMAN TO THE DIRECTORS OF CANCER COUNCIL AUSTRALIA

As lead auditor of Cancer Council Australia for the year ended 30 June 2019, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.



Paul Cheeseman
Partner

BDO East Coast Partnership

Sydney, 22 October 2019

Cancer Council Australia (ABN 91 130 793 725)
Statement of profit or loss and other comprehensive income
As at 30 June 2019

	Notes	2019	2018
		\$	\$
Revenue			
Member subscriptions	1(d)(ii), 4	7,517,930	7,449,591
Grants income	1(d)(iii), 4	5,089,322	435,674
Interest income	1(d)(vi), 4	144,335	130,223
Central marketing fund income	1(d)(v)	218,926	629,995
Other revenue	4	293,977	259,531
Total revenue		13,264,490	8,905,014
Expenses			
Prevention & policy		6,579,895	1,796,464
Information & support		1,876,279	1,462,228
Sale of sun protection products	20	726,143	1,132,109
Marketing of programs & services	20	713,984	620,953
Media & communication		881,617	630,308
Research	20	504,138	395,566
Total mission related expense		11,282,056	6,037,628
Fundraising expense		975,759	1,180,961
Administration & governance	20	334,689	311,998
Special distribution		415,159	961,886
Total expense	5	13,007,663	8,492,473
Income tax expense	1(g)	-	-
Net surplus after income tax expense for the year attributable to the members of Cancer Council Australia		256,827	412,541
Other comprehensive income for the year net of tax		-	-
Total comprehensive income for the year attributable to the members of Cancer Council Australia		256,827	412,541

The accompanying notes form part of these financial statements

Cancer Council Australia (ABN 91 130 793 725)
Statement of financial position
As at 30 June 2019

	Notes	<u>2019</u>	<u>2018</u>
		\$	\$
ASSETS			
Current assets			
Cash & cash equivalents	6	11,758,756	5,003,989
Trade & other receivables	7	7,014,022	7,117,713
Other current assets	8	2,315,287	2,248,077
Total current assets		21,088,065	14,369,779
Non-current assets			
Plant & equipment	9	328,161	335,203
Total non-current assets		328,161	335,203
Total Assets		21,416,226	14,704,982
LIABILITIES			
Current liabilities			
Trade & other payables	10	17,091,327	10,664,922
Provision for employee benefits	11	334,781	347,934
Total current liabilities		17,426,108	11,012,856
Non-current liabilities			
Provision for employee benefits	11	41,492	329
Provision for office make good	11	168,278	168,276
Total non-current liabilities		209,770	168,605
Total Liabilities		17,635,878	11,181,461
Net Assets		3,780,348	3,523,521
FUNDS			
General funds		2,456,868	2,456,868
Research & Special Projects Reserve		1,323,480	1,066,653
Total Funds		3,780,348	3,523,521

The accompanying notes form part of these financial statements

Cancer Council Australia (ABN 91 130 793 725)
Statement of changes in equity
For the year ended 30 June 2019

	General Funds	Research & Special Projects Reserve	Total Funds
Balance at 1 July 2017	2,520,185	590,795	3,110,980
Transfer to/(from) reserves	(475,858)	475,858	
Transfer (to)/from liabilities	-		
Surplus after income tax for the year	412,541		412,541
Other comprehensive income for the year	-		-
Total comprehensive income for the year	(63,317)	475,858	412,541
Balance at 30 June 2018	2,456,868	1,066,653	3,523,521
Balance at 1 July 2018	2,456,868	1,066,653	3,523,521
Transfer to/(from) reserves	(256,827)	256,827	-
Transfer (to)/from liabilities	-	-	-
Surplus after income tax for the year	256,827	-	256,827
Other comprehensive income for the year	-	-	-
Total comprehensive income for the year	-	256,827	256,827
Balance at 30 June 2019	2,456,868	1,323,480	3,780,348

Cancer Council Australia (ABN 91 130 793 725)
Statement of cash flows
For the year ended 30 June 2019

	Note	<u>2019</u>	<u>2018</u>
		\$	\$
<u>Cash flows from operating activities:</u>			
Receipts from member subscriptions, donations and other income (inclusive of GST)		18,002,723	9,677,202
Payments to suppliers, employees and members (inclusive of GST)		(11,240,995)	(10,124,783)
Interest received		144,335	130,223
Net cash received/ (used in) operating activities	16	<u>6,906,063</u>	<u>(317,358)</u>
<u>Cash flows from investing activities:</u>			
Payments for term deposits		(64,080)	
Payment for purchase of plant and equipment	9	(87,216)	(19,313)
Net cash used in investing activities		<u>(151,296)</u>	<u>(19,313)</u>
Net increase / (decrease) in cash & cash equivalents		6,754,767	(336,671)
Cash & cash equivalents at the beginning of the year		<u>5,003,989</u>	<u>5,340,660</u>
Cash & cash equivalents at the end of the year	6	<u>11,758,756</u>	<u>5,003,989</u>

The accompanying notes form part of these financial statements

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2019

Note 1. Statement of significant accounting policies

Cancer Council Australia ("the Company") has adopted Australian Accounting Standards Reduced Disclosure Requirements as set out in AASB 1053. The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards - Reduced Disclosure Requirements of the Australian Accounting Standards Board ("AASB") and the ACNC Act 2012.

The Company is a not-for-profit entity and incorporated Company limited by guarantee domiciled in Australia.

The financial report was authorised for issue by the Directors on 22 October 2019.

NEW, REVISED OR AMENDING ACCOUNTING STANDARDS AND INTERPRETATIONS ADOPTED

The Company has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the AASB that are mandatory for the current reporting period.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the Company.

The following Accounting Standards and Interpretations are most relevant to the Company:

- AASB 2012-3 Amendments to Australian Accounting Standards - Offsetting Financial Assets and Financial Liabilities
- AASB 2013-3 Amendments to AASB 136 - Recoverable Amount Disclosures for Non-Financial Assets
- AASB 2014-1 Amendments to Australian Accounting Standards (Parts A to C)

BASIS OF PREPARATION

These general purpose financial statements have been prepared in accordance with the Australian Charities and Not-for-profit Commission Act 2012 and Australian Accounting Standards - Reduced Disclosure Requirements and Interpretations issued by the AASB. The company is a not-for-profit per financial reporting purpose under Australian Accounting Standards.

REPORTING BASIS AND CONVENTIONS

The financial report has been prepared on an accruals basis (except for the cash flow information and as noted in 1 (d)(i)) and is based on historical costs and does not take into account changing money values or, except where specifically stated, current valuations of non-current assets. The following material accounting policies, which are consistent with the previous period have been adopted in the preparation of this report.

All amounts are in Australian dollars.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2019 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

ACCOUNTING POLICIES

(a) Plant & equipment

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation

Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment (excluding land) over their expected useful lives as follows:

<u>Class of plant and equipment</u>	<u>Useful life</u>
Office equipment	3 - 5 years
Computer equipment	4 years
Leasehold improvements	10 years

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the Company. Gains and losses between the carrying amount and the disposal proceeds are taken to profit and loss.

(b) Provision for employee benefits

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled within 12 months of the reporting date are recognised in current liabilities in respect of employees' services up to the reporting date and are measured at the amounts expected to be paid when the liabilities are settled.

Other long-term employee benefits

The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are recognised in non-current liabilities, provided there is an unconditional right to defer settlement of the liability. The liability is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on national government bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

Defined contribution superannuation expense

Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2019 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(c) **Leased assets**

Lease payments for operating leases, where substantially all the risks and benefits remain with the lessor, are charged as expenses in the periods in which they are incurred.

(d) **Revenue recognition**

Revenue is recognised when it is probable that the economic benefit will flow to the Company and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable.

(i) Donations

The Company, in common with most organisations dependent upon contributions, is unable to establish absolute control over all voluntary donations, due to their nature, prior to their initial entry into the accounting records. Therefore, donations are recorded on the basis of cash received at the time the pledge is made. Donations received as a consequence of formalised national fundraising programs are recorded on a cash basis throughout the year and at year end are accrued to the extent that cash related to the pre-year-end event has subsequently been received.

(ii) Member organisation subscriptions and revenue forwarded to members

Member subscription revenue is recognised on a basis that reflects the timing, nature and value of the benefits provided. Income from national events, donations and royalties is collected by the Company as an agent on behalf of state and territory members and forwarded to members on an annual basis and are reflected in the accounts of members.

	<u>2019</u>	<u>2018</u>
	\$	\$
The details of members' subscriptions received during the year follow:		
Member subscriptions	<u>7,517,930</u>	<u>7,449,591</u>
The details of amounts received by the Company from national events, donations and royalties as an agent of state and territory members follow:		
Amounts forwarded to the Company's state and territory members	<u>7,886,577</u>	<u>8,063,830</u>

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2019 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(iii) Grants

The Company receives grants to undertake certain projects. Where the grant is non-reciprocal, it is recognised as revenue of the Company upon receipt. Associated expenditure for the completion of the grant is recorded as incurred. Where the grant is subject to a reciprocal transfer, a liability associated with the reciprocal transfer is recorded upon receipt of the grant. No income is recorded for reciprocal transfers until conditions associated with the grant are satisfied.

(iv) Royalties

Royalties are earned from the licensing of the use of the Company's endorsement on consumer products and are recorded on an accruals basis as advised by the licensee.

(v) Central Marketing Fund (CMF)

The Central Marketing Fund income received by the Company is contributed by product licensees for the implementation of campaigns to drive incremental sales of Cancer Council branded products and for key brand-building activities that also help to build sun safety awareness in the community. Such contributions received are subject to reciprocal transfer and are recorded as a liability upon receipt. Income is recorded when conditions/payments associated with the contributions are met.

(vi) Interest

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

(vii) Other revenue

Other revenue is recognised when it is received or when the right to receive payment is established.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2019 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(e) Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is current when: it is expected to be realised or intended to be sold or consumed in the normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within twelve months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current.

A liability is current when: it is expected to be settled in the normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within twelve months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. All other liabilities are classified as non-current.

(f) The William L. Rudder Memorial Fund

A voluntary increment to the members' subscriptions of 1% is directed to the William L. Rudder Memorial Fund (the "Fund"). The subscriptions are collected by the Company on behalf of the Fund. The principal activity of the Fund during the financial year was the funding of international cancer travel scholarships. The purpose of these scholarships is to assist the work of voluntary cancer societies in the Asia Pacific region by providing their English-speaking staff and accredited volunteers with non-medical training opportunities.

The Fund is a separate legal entity with the CCA Chair and CEO comprising 2 of the 3 Trustees. CCA provides administrative support to the Fund. All of the subscriptions collected by CCA are forwarded to the Fund, hence there is no balance carried forward in the CCA accounts.

(g) Taxation

The Company is a charitable institution in terms of subsection 50-5 of the Income Tax Assessment Act 1997, as amended; it is therefore exempt from income tax. This exemption has been confirmed by the Australian Taxation Office. The Company holds deductible gift recipient (DGR) status.

(h) Cash & cash equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, and other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.

(i) Trade & other receivables

Other receivables are recognised at amortised cost, less any provision for impairment.

(j) Financial instruments

Initial recognition and measurement

Financial assets and financial liabilities are recognised when the entity becomes a party to the contractual provisions to the instrument. For financial assets, this is equivalent to the date that the entity commits itself to either the purchase or sale of the asset (i.e. trade date accounting is adopted).

Financial instruments are initially measured at fair value plus transaction costs, except where the instrument is classified "at fair value through profit or loss", in which case transaction costs are expensed to profit or loss immediately.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2019 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

Classification and subsequent measurement

Financial instruments are subsequently measured at fair value, amortised cost using the effective interest method, or cost.

Amortised cost is calculated as the amount at which the financial asset or financial liability is measured at initial recognition less principal repayments and any reduction for impairment, and adjusted for any cumulative amortisation of the difference between that initial amount and the maturity amount calculated using the effective interest method.

The effective interest method is used to allocate interest income or interest expense over the relevant period and is equivalent to the rate that discounts estimated future cash payments or receipts (including fees, transaction costs and other premiums or discounts) over the expected life (or when this cannot be reliably predicted, the contractual term) of the financial instrument to the net carrying amount of the financial asset or financial liability. Revisions to expected future net cash flows will necessitate an adjustment to the carrying amount with a consequential recognition of an income or expense item in profit or loss.

(k) Goods and Services Tax (GST)

Revenue, expenses and plant & equipment are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Tax Office. In these circumstances, the GST is recognised as part of the cost of acquisition of the asset or as part of an item of expense. Receivables and payables in balance sheet are shown inclusive of GST. Cash flows are presented in the cash flow statement on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

(l) Trade & other payables

These amounts represent liabilities for goods and services provided to the Company prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

(m) Comparative figures

Comparative figures of the Company for the previous 12 month period are included throughout these statements.

(n) Use of the term "surplus"

The Company is a not-for-profit organisation. As such, the term "profit" is not applicable and the term "surplus" is used where required.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2019 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(o) Critical accounting estimates and judgements

The Directors evaluate estimates and judgements incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the Company.

The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Estimation of useful lives of assets

The Company determines the estimated useful lives and related depreciation and amortisation charges for its plant and equipment. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete. Leasehold improvements are depreciated over the term of the lease of the property.

Long service leave provision

The liability for long service leave is recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

(p) Provisions

Provisions are recognised when the Company has a present (legal or constructive) obligation as a result of a past event, it is probable the Company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. The make good provision represents the estimated costs to make good the premises leased by the Company at the end of the respective lease terms.

Note 2. Nature of the Company

The Company is an incorporated Company Limited by Guarantee under the *Corporations Act 2001*.

There were 8 members of the Company at 30 June 2019.

The members (being the state and territory Cancer Councils) undertake to contribute an amount not exceeding \$10 to the assets of the Company in the event of it being wound up.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2019 (cont'd)

Note 3. Economic dependence

The ability of the Company to maintain its operations is dependent, among other things, on the continuing support of the various state and territory members by way of member subscriptions.

Note 4. Revenue

	<u>2019</u>	<u>2018</u>
	\$	\$
<u>Revenue includes the following</u>		
Membership subscriptions (also refer to note 1 (d) (ii))	7,517,930	7,449,591
Interest Income	144,335	130,223
Central Marketing Fund income (also refer to note 1 (d) (v))	<u>218,926</u>	<u>629,995</u>
	7,881,191	8,209,809
<u>Other revenue</u>		
Grant income	5,089,322	435,674
Research & special projects	174,363	146,506
Other revenue	<u>119,614</u>	<u>113,025</u>
	5,383,299	695,205
Total revenue	<u>13,264,490</u>	<u>8,905,014</u>

The significant increase in grant income recognised in the 2018/19 financial year is due to Cancer Council Australia receiving a \$10m grant from the Commonwealth Government to run Australia's first national mass media campaign to promote bowel cancer screening. Approximately half of these funds were recognised in this financial year, with the balance to be recognised in 2019/20.

Note 5. Other expenses not disclosed elsewhere

Employee benefits expense	<u>4,258,102</u>	<u>4,540,243</u>
---------------------------	------------------	------------------

Note 6. Cash & cash equivalents

Cash on hand	461	750
Cash at bank	<u>11,758,295</u>	<u>5,003,239</u>
	<u>11,758,756</u>	<u>5,003,989</u>

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2019 (cont'd)

Note 7. Trade & other receivables

	<u>2019</u>	<u>2018</u>
<u>Current</u>	<u>\$</u>	<u>\$</u>
Royalties receivable	383,675	730,264
Other amounts receivable	559,481	241,319
Subscriptions due from member cancer organisations	<u>6,070,866</u>	<u>6,146,130</u>
	<u><u>7,014,022</u></u>	<u><u>7,117,713</u></u>

Note 8. Other current assets

Held to maturity - term deposit	2,275,000	2,210,920
Prepayments	<u>40,287</u>	<u>37,157</u>
	<u><u>2,315,287</u></u>	<u><u>2,248,077</u></u>

Note 9. Plant & equipment

Office equipment		
- Office equipment, at cost	377,737	378,516
- Accumulated depreciation	<u>(371,455)</u>	<u>(370,112)</u>
Total office equipment	<u>6,282</u>	<u>8,404</u>
- Computer equipment, at cost	261,621	203,091
- Accumulated depreciation	<u>(166,059)</u>	<u>(175,103)</u>
Total computer equipment	<u>95,562</u>	<u>27,988</u>
Leasehold improvements		
- Leasehold improvements, at cost	702,212	702,214
- Accumulated depreciation	<u>(475,895)</u>	<u>(403,403)</u>
Total leasehold improvements	<u>226,317</u>	<u>298,811</u>
Total plant & equipment	<u><u>328,161</u></u>	<u><u>335,203</u></u>

The net surplus has been determined after charging the following specific expense:

Depreciation of plant & equipment	<u>94,258</u>	<u>98,094</u>
-----------------------------------	---------------	---------------

	Office equipment	Computer equipment	Leasehold improvements	Total
	\$	\$	\$	\$
Balance at 1 Jul 2017	15,512	25,995	384,201	425,708
Additions		19,313		19,313
Revaluation of office make good provision			(11,724)	(11,724)
Depreciation expense	<u>(7,108)</u>	<u>(17,319)</u>	<u>(73,666)</u>	<u>(98,094)</u>
Balance at 30 Jun 2018	8,404	27,988	298,811	335,203
Additions	2,137	85,079	-	87,216
Depreciation expense	<u>(4,259)</u>	<u>(17,505)</u>	<u>(72,494)</u>	<u>(94,258)</u>
Balance at 30 Jun 2019	<u>6,282</u>	<u>95,562</u>	<u>226,317</u>	<u>328,161</u>

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2019 (cont'd)

Note 10. Trade & other payables

	<u>2019</u>	<u>2018</u>
	\$	\$
<u>Current</u>		
Trade creditors	922,643	348,412
Sundry creditors	2,989,228	1,058,413
Income in advance – grants	5,265,812	783,397
Income in advance – other	-	207,364
Amounts due to members	7,913,644	8,267,336
	<u>17,091,327</u>	<u>10,664,922</u>

Note 11. Provisions

<u>Current</u>		
Employee benefits	<u>334,781</u>	<u>347,934</u>
	<u>334,781</u>	<u>347,934</u>
<u>Non-Current</u>		
Employee benefits	41,492	329
Office make good	<u>168,278</u>	<u>168,276</u>
	<u>209,770</u>	<u>168,605</u>

Note 12. Commitments

Non-cancellable operating lease commitments

Non-cancellable operating leases contracted but not capitalised in the financial statements:

Payable

Not longer than one year	465,979	431,640
Longer than one year but not longer than five years	1,094,452	1,512,295
Longer than five years but not longer than ten years	-	-
	<u>1,560,431</u>	<u>1,943,935</u>

The net surplus has been determined after charging the following specific expense:

Rental expense - minimum lease payments	<u>425,822</u>	<u>412,629</u>
---	----------------	----------------

Priority-Driven Research Grant Commitments

Commitments contracted for, but not recognised as liabilities at the balance date, and expected to be funded from annual subscription fees from member:

Payable

Not longer than one year	196,000	84,000
Longer than one year but not longer than five years	<u>204,825</u>	<u>4,983</u>
	<u>400,825</u>	<u>88,983</u>

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2019 (cont'd)

Note 13. Key management personnel disclosures

Compensation

The aggregate compensation made to Directors and key management personnel of the Company is set out below:

<u>2019</u>	<u>2018</u>
\$	\$
<u>972,580</u>	<u>842,407</u>

The increase in key management personnel expenditure in 2018/19 largely reflects payment of accrued benefits to a long-standing member of the management team on departure, and rectification of a prior year underpayment.

Directors' reasonable travel and accommodation expenses are paid for by the Company, but otherwise Directors receive no other payments.

Note 14. Contingent liabilities

There are no contingent liabilities at the end of the year other than those identified elsewhere in the report.

	<u>2019</u>	<u>2018</u>
	\$	\$
Bank guarantee in respect of operating leases	<u>275,000</u>	<u>210,920</u>

Note 15. Events subsequent to reporting date

The Directors are not aware of any significant events that have occurred since the end of the reporting period, which would impact on the financial position of the Company disclosed in the balance sheet as at 30 June 2019 or on the results and cash flows of the Company for the year ended on that date.

Note 16. Reconciliation of cash flows from operating activities with net surplus for the year

	<u>2019</u>	<u>2018</u>
	\$	\$
Net surplus for the year	256,827	412,541
Non-cash flows in net surplus for the year:		
Depreciation	94,258	98,094
Changes in assets and liabilities:		
Decrease in receivables	400,493	1,208,637
(Increase) in other assets	(3,131)	(35,837)
Increase in provisions	28,010	3,510
Increase/(decrease) in payables	<u>6,129,606</u>	<u>(2,004,303)</u>
Net cash from/ (used in) operating activities	<u><u>6,906,063</u></u>	<u><u>(317,358)</u></u>

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2019 (cont'd)

Note 17. Remuneration of the Auditor

During the year, the following fees were paid or payable for services provided by the Auditor, BDO East Coast Partnership to the Company:

	<u>2019</u>	<u>2018</u>
	\$	\$
External audit of the financial statement	<u>24,600</u>	<u>24,150</u>

Note 18. Company Details

The registered office and principal place of business of the Company is:

Level 14, 477 Pitt Street
Sydney NSW 2000 Australia

The Company operates entirely in Australia as a Health Promotion Charity.

Note 19. Related party transactions

Key management personnel

Disclosures relating to key management personnel are set out in note 13.

Transactions with related parties

The only related parties were the members and that there were no related party transactions other than those already disclosed during the current and previous financial year.

Receivable from and payable to related parties

Other than those already disclosed, there were no trade receivables from or trade payables to related parties at the current and previous reporting date.

Loans to/from related parties

There were no loans to or from related parties at the current and previous reporting date.

Note 20. Expenditure

Sale of sun protection products

Cancer Council Australia (CCA) manages retail and licensing arrangements to distribute sun protection products, and to promote preventative behaviours to reduce the incidence of skin cancers, on behalf of CCA's state and territory members. Accordingly, income generated from this activity is recognised in CCA's state and territory members' financial accounts, and in turn used by them to deliver research, support and prevention programs at a local level.

Research

Collectively, Cancer Council Australia and its state and territory members fund approximately \$60 million of cancer research in Australia each year, more than any other non-government entity. Reflecting long-standing practice, CCA's investment in research is restricted to priority research programs and partnership grants. More information can be found in the Cancer Council Research Report found at cancer.org.au.

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2019 (cont'd)

Note 20. Expenditure (cont'd)

Administration and governance

Administration and governance costs reflect costs required to operate as a corporate entity and provide best practice governance. Recent trends in these costs reflect the ongoing focus on improved governance and performance.

Other costs incurred to support the delivery of mission and fundraising work, including a proportion of our information technology, human resources, learning and development, financial administration and occupancy costs, are attributed to each functional area of Cancer Council Australia's work to reflect the cost of delivering these functions.

Marketing of programs & services

Cancer Council Australia and its state and territory members work together towards a shared vision of a cancer free future. To achieve this we invest each year in research, prevention, and advocacy programs, and fund many support and information services.

Our Marketing teams work is to increase the awareness of the programs we fund, and of the services we provide to Australians with a cancer diagnosis, and their families and friends.


More information can be found in the Cancer Council Impact Report found at impact.cancer.org.au.

Cancer Council Australia (ABN 91 130 793 725)
Financial report for the year ended 30 June 2019
Directors' Declaration

In the Directors' opinion:

1. The attached financial statements and notes comply with the ACNC Act 2012, Australian Accounting Standards – Reduced Disclosure Requirements, the ACNC Regulations 2013 and other mandatory professional reporting requirements;
2. The attached financial statements and notes thereto give a true and fair view of the Company's financial position as at 30 June 2019 and of its performance for the financial year ended on that date; and
3. There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the Directors by:



Mr Hugh Harley
Chair



Dr John Laker

Sydney
22 October 2019

INDEPENDENT AUDITOR'S REPORT

To the members of Cancer Council Australia

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Cancer Council Australia, which comprises the statement of financial position as at 30 June 2019, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies, and the responsible entities' declaration.

In our opinion the accompanying financial report of Cancer Council Australia, is in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (i) Giving a true and fair view of the registered entity's financial position as at 30 June 2019 and of its financial performance for the year then ended; and
- (ii) Complying with Australian Accounting Standards - Reduced Disclosure Requirements and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the registered entity in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of responsible entities for the Financial Report

The responsible entities of the registered entity are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and the ACNC Act, and for such internal control as the responsible entities determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.



In preparing the financial report, responsible entities are responsible for assessing the registered entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the responsible entities either intends to liquidate the registered entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the registered entity's financial reporting process.

Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at:

http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf

This description forms part of our auditor's report.

BDO East Coast Partnership

A small, stylized version of the BDO logo, consisting of the letters 'BDO' in a cursive script.

A handwritten signature in cursive script that reads 'Paul Cheeseman'.

Paul Cheeseman
Partner

Sydney, 22 October 2019